In Illinois, the statute of limitations for Reglan (metoclopramide) tardive dyskinesia claims generally requires filing within two years from when the injury was discovered or should have been discovered. However, specific deadlines can vary based on individual circumstances. Consult a qualified attorney to determine the applicable time limit for your case.
If you or a loved one has taken Reglan and noticed involuntary movements, you may be concerned about tardive dyskinesia. The medical community has long recognized that certain medications carry risks requiring careful monitoring. This page summarizes what current evidence can and cannot tell us about the diagnosis and follow-up of Reglan-induced tardive dyskinesia.
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. However, its association with tardive dyskinesia (TD) has led to significant litigation, particularly regarding the adequacy of warnings and the statute of limitations for claims in Illinois. This narrative examines the clinical and risk factors relevant to affected patients. Tardive dyskinesia is a syndrome of potentially irreversible, disfiguring involuntary movements, typically involving the face or tongue, and sometimes the trunk or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition can be masked by metoclopramide, which may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Clinical presentation often includes repetitive, involuntary movements such as lip smacking, tongue protrusion, grimacing, or rapid eye blinking. In severe cases, movements may involve the limbs or torso, impairing daily function and quality of life.
Reglan’s pharmacology involves dopamine receptor antagonism, which is the mechanistic pathway linked to TD. The drug’s boxed warning states that metoclopramide can cause TD, and the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For gastroesophageal reflux, the maximum approved treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the label advises avoiding treatment longer than 12 weeks, and if longer use is unavoidable, routine monitoring for TD signs is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients have been prescribed Reglan for extended periods, sometimes years, leading to cumulative exposure that heightens TD risk. The adequacy of warnings is a central issue in litigation. The FDA-approved label includes a boxed warning emphasizing TD risk, contraindication in patients with a history of TD, and instructions to use the shortest duration and discontinue if symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, plaintiffs often argue that prescribers and patients were not adequately informed about the potential for irreversible harm, especially with long-term use beyond 12 weeks. The label also notes that Reglan is not recommended for pediatric patients due to TD risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
In Illinois, the statute of limitations for product liability claims generally requires filing within two years of the date the injury was discovered or should have been discovered. For TD, this timeline is complicated because symptoms may develop gradually and may be initially attributed to other causes. The latency period between Reglan exposure and documented harm can range from months to years, with some patients developing TD after only a few weeks of treatment, while others experience onset after prolonged use. This variability affects when the statute of limitations begins to run. Settlement considerations for affected patients include the severity of TD, duration of Reglan use, and evidence of inadequate warnings. Many settlements have been reached in multidistrict litigation, with compensation varying based on factors such as age, extent of disability, and medical expenses. Patients in Illinois must be aware that the discovery rule may apply, meaning the statute of limitations starts when the patient knew or reasonably should have known that Reglan caused their TD. Medical records documenting the timeline of Reglan use and TD onset are critical for establishing this date. Additionally, the label’s warning about masking TD symptoms complicates diagnosis, as patients may not recognize movements as drug-related until later.
In summary, Reglan-associated TD presents a complex interplay of clinical presentation, pharmacological risk, and legal timelines. Patients in Illinois should seek prompt medical evaluation if they experience involuntary movements after Reglan use, and consult legal counsel to assess their claim within the applicable statute of limitations. The evidence underscores the importance of adhering to prescribed treatment durations and monitoring for early signs of TD. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Illinois, the statute of limitations for product liability claims generally requires filing within two years of the date the injury was discovered or should have been discovered. For tardive dyskinesia, this timeline can be complicated because symptoms may develop gradually. The discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Reglan caused their TD. It is crucial to consult an attorney promptly to preserve your claim.
Tardive dyskinesia is often irreversible, but symptoms may improve or resolve after discontinuation of Reglan. Early detection and cessation of the drug are important. However, some patients experience persistent symptoms. Treatment options include medications like valbenazine or deutetrabenazine, but there is no guaranteed cure. Monitoring and medical management are essential.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.